Hereditary Angioedema Market Overview

The report is titled ‘Hereditary Angioedema Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the hereditary angioedema market is the main objective of the report, which further consists of the market opportunity and insights of the data involved in the making of the respective market. The hereditary angioedema market is expected to grow at a significant rate in the near future.

The global hereditary angioedema market in 2020 is estimated for more than US$ 2,867.8 Mn and expected to reach a value of US$ 9,551.6 Mn by 2028 with a significant CAGR of 16.3%.

Hereditary Angioedema Market Segmentation

The global hereditary angioedema market is categorized under various classes such as drug class, route of administration, distribution channel, and region. The drug class segment further divided into four other categories such as kallikrein inhibitor, selective bradykinin B2 receptor antagonist, C1 esterase inhibitor, and others. C1 esterase inhibitor segment is further divided into cinryze, berinert, and rucones.

The route of administration segment further divided into three other categories such as intravenous, subcutaneous, and oral.

The distribution channel segment further divided into two other categories such as hospital, retail pharmaceutical.

Hereditary Angioedema Market Dynamics

Increasing per capita income is allowing professionals and citizens to opt for better quality healthcare services. It allows the doctors or physicians to provide the latest and expensive treatment to their patients; whereas, on the other hand, it facilitates an improved version of traditional treatments to the patients, thus, ensuring the increased life expectancy of the patients to some extent. It also regulates the cycle of routine body check-ups, ensuring the sound health of body and mind; in addition, it is also notifying the professionals about the actual health condition along with the might be upcoming problems or deteriorated health conditions

Hereditary Angioedema Market Key Players

The global hereditary angioedema market is mainly dominated by Biocryst Pharmaceuticals, INC., CSL Limited, IBIO INC., IONIS Pharmaceutical, Pharming Group NV, Santarus, INC., and Shire PLC.

Hereditary Angioedema Market Regional Level Analysis

On the basis of region, the global hereditary angioedema market is segmented into six regions namely North America, Latin America, Asia Pacific, Europe, Middle East, and Africa. Hereditary angioedema (HAE) is a rare disease and the diagnosis of HAE challenging in children. It may be due to the lack of awareness, diagnostic testing limitations, and communication difficulties along with the differential diagnosis of the symptoms of this disorder. This may further result in reduced quality of life, accounting to the delay in diagnosis along with sub-optimal treatment of symptoms, which is the major factor that hinders the growth of this market.

MMC Overview on Hereditary Angioedema Market Report

The non-identical approach of Meridian Market Consultants stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give a better opportunity for the customers to put their effort.

A research report on the Hereditary Angioedema Market by Meridian Market Consultants is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that support the market and the factors that are acting as impedance for the growth of the market.

Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth include (but not restricted to):

•    New product designs and launches

•    Current product compliance

•    Reimbursement

•    Concerns for use of Hereditary Angioedema

•    Advantages of Hereditary Angioedema

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at a regional level and in major countries globally for providing regional insights into the product segment in the report. This helps our clients to make an informed decision.

A mix of top-down and bottom-up approach is followed to arrive at and validate our market value estimations. For a product segment wherein one/two manufacturer(s) dominates the market, its product sales, previous growth rates, and market expansion plans are considered to generate market share in the global market.

1.    Global Hereditary Angioedema Market Report Overview

1.1.    Introduction

1.2.    Report Description

1.3.    Methodology

2.    Global Hereditary Angioedema Market Overview

2.1.    Introduction

2.1.1.    Market Definition

2.1.2.    Market Taxonomy

2.2.    Executive Summary

2.3.    Global Hereditary Angioedema Market Snapshot

2.4.    Global Hereditary Angioedema Market Size and Forecast, 2020–2028

2.4.1.    Introduction

2.4.2.    Market Value Forecast and Annual Growth Rate (AGR) Comparison (2020–2028)

2.5.    Global Hereditary Angioedema Market Dynamics

2.5.1.    Drivers

2.5.2.    Restraints

2.5.3.    Opportunity

2.5.4.    Trends

2.6.    Key Regulations

2.7.    Porter’s Five Forces Model

3.    Global Hereditary Angioedema Market, By Drug Class

3.1.    Introduction

3.1.1.    Annual Growth Rate Comparison, By Drug Class

3.1.2.    BPS Analysis, By Drug Class

3.2.    Market Revenue (US$Mn) Forecast, By Drug Class

3.2.1.    C1 esterase inhibitor

3.2.1.1.    Cinryze

3.2.1.2.    Berinert

3.2.1.3.    Ruconest

3.2.2.    Selective Bradykinin B2 Receptor Antagonist

3.2.3.    Kallikrein Inhibitors

3.2.4.    Others

3.3.    Global Hereditary Angioedema Market Attractiveness Index, By Drug Class

4.    Global Hereditary Angioedema Market, Route of Administration

4.1.    Introduction

4.1.1.    Annual Growth Rate Comparison, Route of Administration

4.1.2.    BPS Analysis, Route of Administration

4.2.    Market Revenue (US$Mn) Forecast, Route of Administration

4.2.1.    Intravenous

4.2.2.    Sub-Cutaneous

4.2.3.    Oral

4.3.    Global Hereditary Angioedema Market Attractiveness Index, Route of Administration

5.    Global Hereditary Angioedema Market, By Distribution Channel

5.1.    Introduction

5.1.1.    Annual Growth Rate Comparison, By Distribution Channel

5.1.2.    BPS Analysis, By Distribution Channel

5.2.    Market Revenue (US$Mn) Forecast, By Distribution Channel

5.2.1.    Hospital

5.2.2.    Retail Pharmaceutical

5.3.    Global Hereditary Angioedema Market Attractiveness Index, By Distribution Channel

6.    Global Hereditary Angioedema Market, By Region

6.1.    Introduction

6.1.1.    Annual Growth Rate Comparison, By Region

6.1.2.    BPS Analysis, By Region

6.2.    Market Revenue (US$Mn) Forecast, By Region

6.2.1.    North America

6.2.2.    Latin America

6.2.3.    Europe

6.2.4.    Asia Pacific

6.2.5.    Middle East

6.2.6.    Africa

6.3.    Global Hereditary Angioedema Market Attractiveness Index, By Region

7.    North America Hereditary Angioedema Market Analysis and Forecast, 2020–2028

7.1.    Introduction

7.1.1.    Annual Growth Rate Comparison, By Country

7.1.2.    BPS Analysis, By Country

7.2.    Market Revenue (US$Mn) Forecast, By Country

7.2.1.    U.S. Hereditary Angioedema Market

7.2.2.    Canada Hereditary Angioedema Market

7.3.    North America Hereditary Angioedema Market, By Drug Class

7.3.1.    C1 esterase inhibitor

7.3.1.1.    Cinryze

7.3.1.2.    Berinert

7.3.1.3.    Ruconest

7.3.2.    Selective Bradykinin B2 Receptor Antagonist

7.3.3.    Kallikrein Inhibitors

7.3.4.    Others

7.4.    North America Hereditary Angioedema Market, Route of Administration

7.4.1.    Intravenous

7.4.2.    Sub-Cutaneous

7.4.3.    Oral

7.5.    North America Hereditary Angioedema Market Attractiveness Index

7.5.1.    By Country

7.5.2.    By Drug Class

7.5.3.    Route of Administration

7.5.4.    By Distribution Channel

8.    Latin America Hereditary Angioedema Market Analysis and Forecast, 2020–2028

8.1.    Introduction

8.1.1.    Annual Growth Rate Comparison, By Country

8.1.2.    BPS Analysis, By Country

8.2.    Market (US$Mn) Forecast, By Country

8.2.1.    Brazil Hereditary Angioedema Market

8.2.2.    Mexico Hereditary Angioedema Market

8.2.3.    Argentina Hereditary Angioedema Market

8.2.4.    Rest of Latin America Hereditary Angioedema Market

8.3.    Latin America Hereditary Angioedema Market, By Drug Class

8.3.1.    C1 esterase inhibitor

8.3.1.1.    Cinryze

8.3.1.2.    Berinert

8.3.1.3.    Ruconest

8.3.2.    Selective Bradykinin B2 Receptor Antagonist

8.3.3.    Kallikrein Inhibitors

8.3.4.    Others

8.4.    Latin America Hereditary Angioedema Market, Route of Administration

8.4.1.    Intravenous

8.4.2.    Sub-Cutaneous

8.4.3.    Oral

8.5.    Latin America Hereditary Angioedema Market, By Distribution Channel

8.5.1.    Hospital

8.5.2.    Retail Pharmaceutical

8.6.    Latin America Hereditary Angioedema Market Attractiveness Index

8.6.1.    By Country

8.6.2.    By Drug Class

8.6.3.    Route of Administration

8.6.4.    By Distribution Channel

9.    Europe Hereditary Angioedema Market Analysis and Forecast, 2020–2028

9.1.    Introduction

9.1.1.    Annual Growth Rate Comparison, By Country

9.1.2.    BPS Analysis, By Country

9.2.    Market (US$Mn) Forecast, By Country

9.2.1.    U.K. Hereditary Angioedema Market

9.2.2.    Germany Hereditary Angioedema Market

9.2.3.    Italy Hereditary Angioedema Market

9.2.4.    France Hereditary Angioedema Market

9.2.5.    Spain Hereditary Angioedema Market

9.2.6.    Russia Hereditary Angioedema Market

9.2.7.    Poland Hereditary Angioedema Market

9.2.8.    BENELUX Hereditary Angioedema Market

9.2.9.    NORDIC Hereditary Angioedema Market

9.2.10.    Rest of Europe Hereditary Angioedema Market

9.3.    Europe Hereditary Angioedema Market, By Drug Class

9.3.1.    C1 esterase inhibitor

9.3.1.1.    Cinryze

9.3.1.2.    Berinert

9.3.1.3.    Ruconest

9.3.2.    Selective Bradykinin B2 Receptor Antagonist

9.3.3.    Kallikrein Inhibitors

9.3.4.    Others

9.4.    Europe Hereditary Angioedema Market, Route of Administration

9.4.1.    Intravenous

9.4.2.    Sub-Cutaneous

9.4.3.    Oral

9.5.    Europe Hereditary Angioedema Market, By Distribution Channel

9.5.1.    Hospital

9.5.2.    Retail Pharmaceutical

9.6.    Europe Hereditary Angioedema Market Attractiveness Index

9.6.1.    By Country

9.6.2.    By Drug Class

9.6.3.    Route of Administration

9.6.4.    By Distribution Channel

10.    Asia Pacific Hereditary Angioedema Market Analysis and Forecast, 2020–2028

10.1.    Introduction

10.1.1.    Annual Growth Rate Comparison, By Country

10.1.2.    BPS Analysis, By Country

10.2.    Market (US$Mn) Forecast, By Country

10.2.1.    China Hereditary Angioedema Market

10.2.2.    India Hereditary Angioedema Market

10.2.3.    Japan Hereditary Angioedema Market

10.2.4.    Australia and New Zealand Hereditary Angioedema Market

10.2.5.    South Korea Hereditary Angioedema Market

10.2.6.    ASEAN Hereditary Angioedema Market

10.2.7.    Rest of Asia Pacific Hereditary Angioedema Market

10.3.    Asia Pacific Hereditary Angioedema Market, By Drug Class

10.3.1.    C1 esterase inhibitor

10.3.1.1.    Cinryze

10.3.1.2.    Berinert

10.3.1.3.    Ruconest

10.3.2.    Selective Bradykinin B2 Receptor Antagonist

10.3.3.    Kallikrein Inhibitors

10.3.4.    Others

10.4.    Asia Pacific Hereditary Angioedema Market, Route of Administration

10.4.1.    Intravenous

10.4.2.    Sub-Cutaneous

10.4.3.    Oral

10.5.    Asia Pacific Hereditary Angioedema Market, By Distribution Channel

10.5.1.    Hospital

10.5.2.    Retail Pharmaceutical

10.6.    Asia Pacific Hereditary Angioedema Market Attractiveness Index

10.6.1.    By Country

10.6.2.    By Drug Class

10.6.3.    Route of Administration

10.6.4.    By Distribution Channel

11.    Middle East Hereditary Angioedema Market Analysis and Forecast, 2020–2028

11.1.    Introduction

11.1.1.    Annual Growth Rate Comparison, By Country

11.1.2.    BPS Analysis, By Country

11.2.    Market (US$Mn) Forecast, By Country

11.2.1.    GCC Countries Hereditary Angioedema Market

11.2.2.    Israel Hereditary Angioedema Market

11.2.3.    Oman Hereditary Angioedema Market

11.2.4.    Rest of Middle East Hereditary Angioedema Market

11.3.    Middle East Hereditary Angioedema Market, By Drug Class

11.3.1.    C1 esterase inhibitor

11.3.1.1.    Cinryze

11.3.1.2.    Berinert

11.3.1.3.    Ruconest

11.3.2.    Selective Bradykinin B2 Receptor Antagonist

11.3.3.    Kallikrein Inhibitors

11.3.4.    Others

11.4.    Middle East Hereditary Angioedema Market, Route of Administration

11.4.1.    Intravenous

11.4.2.    Sub-Cutaneous

11.4.3.    Oral

11.5.    Middle East Hereditary Angioedema Market, By Distribution Channel

11.5.1.    Hospital

11.5.2.    Retail Pharmaceutical

11.6.    Middle East Hereditary Angioedema Market Attractiveness Index

11.6.1.    By Country

11.6.2.    By Drug Class

11.6.3.    Route of Administration

11.6.4.    By Distribution Channel

12.    Africa Hereditary Angioedema Market Analysis and Forecast, 2020–2028

12.1.    Introduction

12.1.1.    Annual Growth Rate Comparison, By Country

12.1.2.    BPS Analysis, By Country

12.2.    Market (US$Mn) Forecast, By Country

12.2.1.    South Africa Hereditary Angioedema Market

12.2.2.    Egypt Hereditary Angioedema Market

12.2.3.    North Africa Hereditary Angioedema Market

12.2.4.    Rest of Africa Hereditary Angioedema Market

12.3.    Africa Hereditary Angioedema Market, By Drug Class

12.3.1.    C1 esterase inhibitor

12.3.1.1.    Cinryze

12.3.1.2.    Berinert

12.3.1.3.    Ruconest

12.3.2.    Selective Bradykinin B2 Receptor Antagonist

12.3.3.    Kallikrein Inhibitors

12.3.4.    Others

12.4.    Africa Hereditary Angioedema Market, Route of Administration

12.4.1.    Intravenous

12.4.2.    Sub-Cutaneous

12.4.3.    Oral

12.5.    Africa Hereditary Angioedema Market, By Distribution Channel

12.5.1.    Hospital

12.5.2.    Retail Pharmaceutical

12.5.3.    Services

12.6.    Africa Hereditary Angioedema Market Attractiveness Index

12.6.1.    By Country

12.6.2.    By Drug Class

12.6.3.    Route of Administration

12.6.4.    By Distribution Channel

13.    Recommendation

13.1.    Market Strategy

14.    Competitive Landscape

14.1.    Competition Dashboard

14.2.    List and Company Overview of Global Key Players

14.3.    Company Profiles

14.3.1.    Biocryst Pharmaceuticals

14.3.1.1.    Company Overview

14.3.1.2.    Financial Overview

14.3.1.3.    Product Portfolio

14.3.1.4.    Key Developments

14.3.1.5.    Business Strategies

14.3.2.    CSL Limited

14.3.3.    IBIO INC.

14.3.4.    IONIS Pharmaceutical

14.3.5.    Pharming Group NV

14.3.6.    Santarus, INC.

14.3.7.    Shire PLC.

15.    Acronyms